Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
AMGEN INC et al v. MYLAN INC. et al
Case Number:
2:17-cv-01235
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
August 22, 2019
Mylan Partially Beats Amgen Neulasta Biosimilar Claims
In light of a recent Federal Circuit decision, Amgen Inc. can no longer allege that Mylan Inc.'s proposed Neulasta biosimilar infringed one of its patents, a Pennsylvania federal court ruled Wednesday, granting a joint request from both parties to nix the claim.
-
April 09, 2018
Amgen's Patent Not Used In Neulasta Biosimilar, Mylan Says
Mylan Inc.'s proposed Neulasta biosimilar doesn't use the salt pairs covered in a patent Amgen Inc. is accusing it of infringing, Mylan told a Pennsylvania federal court Friday, hoping to get the claim killed by relying on an argument that got a similar suit over the patent dismissed last month.
-
September 25, 2017
Amgen Hits Mylan With Patent Suit Over Neulasta Biosimilar
Mylan Inc. infringed two of Amgen Inc.'s patents when seeking to get its biosimilar of Amgen's blockbuster anti-infection medicine Neulasta on the market before the patents expired, the biologic maker told a Pennsylvania federal court Friday.